Bone News and Research

RSS

Exelixis commences cabozantinib phase 3 pivotal trial in mCRPC

Exelixis, Inc. today announced the initiation of COMET-1, a phase 3 pivotal trial of cabozantinib in men with metastatic castration-resistant prostate cancer.

31 May 2012

CytRx INNO-206 doxorubicin conjugate shows anti-multiple myeloma effects

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that in animal and in vitro studies, its tumor-targeting doxorubicin conjugate INNO-206 showed anti-multiple myeloma effects and enhanced the anti-tumor effects of bortezomib, which is approved for the treatment of relapsed multiple myeloma.

30 May 2012

Beike stem cell bank in China granted AABB accreditation

Beike Biotechnology Co., Ltd announced that it has been awarded AABB accreditation for cord blood and cord tissue banking. This accreditation has been granted following an intensive on-site assessment by AABB assessors and establishes that the level of medical, technical and administrative performance within the facility is in accordance with the AABB standards or exceeds those set by AABB.

30 May 2012

FRAX tool ‘resistant’ to osteoporosis treatment effects

Osteoporosis therapy does not invalidate the use of the World Health Organization’s fracture risk assessment system for fracture prediction, study findings indicate.

30 May 2012

Exelixis files NDA with FDA for cabozantinib to treat MTC

Exelixis, Inc. today announced that it has completed the filing of its rolling New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for cabozantinib as a treatment for patients with progressive, unresectable, locally advanced, or metastatic medullary thyroid cancer.

30 May 2012

Studies outline dilemmas on new generic heart drugs, hormone replacement therapy

One heart drug's move to generic status has complicated treatment options for some patients and doctors, the Wall Street Journal reports. Also, another study raises concerns about hormone replacement therapy in women.

30 May 2012

First study to look at link between vitamin D and onset of new mobility disability in older adults

Older adults who don't get enough vitamin D - either from diet, supplements or sun exposure - may be at increased risk of developing mobility limitations and disability, according to new research from Wake Forest Baptist Medical Center.

30 May 2012

CHOC Children's research project receives $5.5M CIRM grant

A CHOC Children's research project, under the direction of Philip H. Schwartz, Ph.D., senior scientist at the CHOC Children's Research Institute and managing director of the facility's National Human Neural Stem Cell Resource, has been awarded a $5.5 million grant from the California Institute for Regenerative Medicine.

30 May 2012

Link between women's health issues and gum disease

Women, keep those toothbrushes and dental floss handy. A comprehensive review of women's health studies by Charlene Krejci, associate clinical professor at the Case Western Reserve University School of Dental Medicine, has shown a link between women's health issues and gum disease.

30 May 2012

ASCs promising source of cells for use in plastic surgery and regenerative medicine

Adipose stem cells (ASCs)—stem cells derived from fat—are a promising source of cells for use in plastic surgery and regenerative medicine, according to a special review in the June issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

30 May 2012

USPTO issues patent to Corgenix’s AspirinWorks technology

Corgenix Medical Corporation, a worldwide developer and marketer of diagnostic test kits, has been issued an additional U.S. patent covering its AspirinWorks technology.

30 May 2012

Secreted vesicles play role in spread of cancer

Cancer researchers have known for well over a century that different tumor types spread only to specific, preferred organs. But no one has been able to determine the mechanisms of organ specific metastasis, the so-called "soil and seed" theory of 1889. New details that could help shed light on this hypothesis have been provided by a team of researchers from Weill Cornell Medical College, Memorial Sloan-Kettering Cancer Center, and their collaborators, proposing a new mechanism controlling cancer metastasis that offers fresh diagnostic and treatment potential.

29 May 2012

Spectrum initiates enrollment in RenaZorb Phase 1 trial in healthy volunteers

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology and hematology, today announced the initiation of patient enrollment in a Phase 1 clinical trial evaluating the safety and tolerability of RenaZorb in healthy volunteers.

29 May 2012

AMS, Expanding Orthopedics partner to distribute XPED system in Italy

Expanding Orthopedics Inc. announced that it has entered into an exclusive distribution agreement with Advanced Medical Systems for the distribution of its unique XPED Expanding Pedicle Screw System in Italy.

29 May 2012

Abbott to highlight latest investigational research findings on HUMIRA at EULAR 2012

Abbott scientists and independent researchers will highlight the latest investigational research findings on HUMIRA (adalimumab) at the European League Against Rheumatism (EULAR) Congress in Berlin, Germany, from 6-9 June, 2012.

29 May 2012

New technique more sensitive in detecting bone loss than X-ray method

Are your bones getting stronger or weaker? Right now, it's hard to know. Scientists at Arizona State University and NASA are taking on this medical challenge by developing and applying a technique that originated in the Earth sciences. In a new study, this technique was more sensitive in detecting bone loss than the X-ray method used today, with less risk to patients. Eventually, it may find use in clinical settings, and could pave the way for additional innovative biosignatures to detect disease.

29 May 2012

Medivir initiates MIV-711 phase I trial in bone disorders

Medivir AB, a research-based pharmaceutical company focused on infectious diseases, announced today that a phase I clinical trial has been initiated with its investigational drug, MIV-711, a cathepsin K inhibitor for the treatment of bone disorders characterized by excessive bone resorption such as osteoporosis, osteoarthritis and bone metastases.

28 May 2012

Tulane to initiate XM-ONE clinical trial in kidney transplantation

Tulane University Hospital, New Orleans, LA, USA will in May start a prospective trial in Kidney Transplantation investigating the potential of cross match XM-ONE as part of the risk assessment of their patients.

28 May 2012

UC Davis mathematicians help biologists to understand platelet formation

UC Davis mathematicians have helped biologists figure out why platelets, the cells that form blood clots, are the size and shape that they are. Because platelets are important both for healing wounds and in strokes and other conditions, a better understanding of how they form and behave could have wide implications.

28 May 2012

UCLA geneticists identify mutation responsible for IMAGe syndrome

UCLA geneticists have identified the mutation responsible for IMAGe syndrome, a rare disorder that stunts infants' growth. The twist? The mutation occurs on the same gene that causes Beckwith-Wiedemann syndrome, which makes cells grow too fast, leading to very large children.

28 May 2012